Pulmonary-Allergy Drug Advisory Committee; Cancellation, 6518 [E8-1959]
Download as PDF
<![CDATA[
6518
Federal Register / Vol. 73, No. 23 / Monday, February 4, 2008 / Notices
Dated: January 24, 2008.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E8–2013 Filed 2–1–08; 8:45 am]
BILLING CODE 4163–18–P
Description: A voluntary program
which provides State Child Support
Enforcement agencies, upon their
request, access to the earned and
unearned income information reported
to IRS by employers and financial
institutions. The IRS 1099 information
is used to locate noncustodial parents
and to verify income and employment.
Respondents: State IV–D programs.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Project 1099.
OMB No.: 0970–0183.
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
1099 Record specifications .............................................................................
IRS Safeguarding Certification Letter ..............................................................
Estimated Total Annual Burden
Hours: 1,296.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
Services, 370 L’enfant Promenade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
should be identified by the title of the
information collection. E-mail address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following:
Office of Management and Budget,
Paperwork Reduction Project, Fax: 202–
395–6974, Attn: Desk Officer for the
Administration for Children and
Families.
54
54
SUMMARY: The meeting of the
Pulmonary-Allergy Drugs Advisory
Committee scheduled for February 20,
2008, is cancelled. This meeting was
announced in the Federal Register of
December 21, 2007 (72 FR 72737).
FOR FURTHER INFORMATION CONTACT:
Teresa A. Watkins, Center for Drug
Evaluation and Research (HFD–21),
Food and Drug Administration, 5630
Fishers Lane (for express delivery, rm.
1093), Rockville, MD 20857, 301–827–
7001, FAX: 301–827–6776, e-mail:
Teresa.Watkins@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512545. Please call the Information
Line for up-to-date information on this
meeting.
ebenthall on PRODPC61 with NOTICES
Food and Drug Administration
Pulmonary-Allergy Drug Advisory
Committee; Cancellation
Food and Drug Administration,
Notice.
VerDate Aug<31>2005
15:15 Feb 01, 2008
Jkt 214001
1.96
.48
1,270
26
Clinical Center, including consideration
of personnel qualifications and
performance and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Board of Scientific
Counselors of the NIH Clinical Center.
Date: February 25, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate Imaging
Sciences Review.
Place: National Institutes of Health,
Building 10, 10 Center Drive, CRC—Room 4–
2551, Bethesda, MD 20892.
Contact Person: David K. Henderson, MD,
Deputy Director for Clinical Care, Office of
the Director, Clinical Center, National
Institutes of Health, Building 10, Room 6–
1480, Bethesda, MD 20892, (301) 496–3515.
Dated: January 24, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–465 Filed 2–1–08; 8:45 am]
BILLING CODE 4160–01–S
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Closed
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
12
1
Total burden
hours
Dated: January 29, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8–1959 Filed 2–1–08; 8:45 am]
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. appendix 2), notice
is hereby given of a meeting of the
Board of Scientific Counselors of the
NIH Clinical Center.
The meetings will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(6), title 5 U.S.C., as amended,
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
Pursuant to section 120(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
BILLING CODE 4184–01–M
HHS.
Average
burden hours
per response
National Institutes of Health
Dated: January 25, 2008.
Janean Chambers,
Reports Clearance Officer.
[FR Doc. 08–446 Filed 2–1–08; 8:45 am]
AGENCY:
Number of
responses per
respondent
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
E:\FR\FM\04FEN1.SGM
04FEN1
]]>Agencies
[Federal Register Volume 73, Number 23 (Monday, February 4, 2008)]
[Notices]
[Page 6518]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-1959]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Pulmonary-Allergy Drug Advisory Committee; Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Pulmonary-Allergy Drugs Advisory Committee
scheduled for February 20, 2008, is cancelled. This meeting was
announced in the Federal Register of December 21, 2007 (72 FR 72737).
FOR FURTHER INFORMATION CONTACT: Teresa A. Watkins, Center for Drug
Evaluation and Research (HFD-21), Food and Drug Administration, 5630
Fishers Lane (for express delivery, rm. 1093), Rockville, MD 20857,
301-827-7001, FAX: 301-827-6776, e-mail: Teresa.Watkins@fda.hhs.gov, or
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572
in the Washington, DC area), code 3014512545. Please call the
Information Line for up-to-date information on this meeting.
Dated: January 29, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8-1959 Filed 2-1-08; 8:45 am]
BILLING CODE 4160-01-S
